In vivo, intervention with ASIC1a and RIPK3 significantly alleviated RA progression, highlighting that targeting ASIC1a and its downstream metabolic pathways may offer a promising therapeutic strategy to control synovial invasion and mitigate RA progression. This evidence concerns the gene RIPK3 and rheumatoid arthritis.